

Table 6.6h
Persistency of Discharge Regimen by Follow-up Period, 2003 to 2007
Recipients with Pancreas Transplant Alone (PTA) Transplants

| | Year of Transplant | | | | |
|--|--------------------|--------|--------|--------|--------|
| | 2003 | 2004 | 2005 | 2006 | 2007 |
| Discharge Regimen (w/ or w/o Steroid Use) | | | | | |
| CyA+MMF | | | | | |
| At Discharge (N) | 2 | 1 | - | 2 | 3 |
| At Discharge (%) | 100.0% | 100.0% | - | 100.0% | 100.0% |
| 6 Months PostTx (%) | 100.0% | 100.0% | - | 0.0% | 100.0% |
| 1 Year PostTx (%) | 100.0% | 100.0% | - | 0.0% | 66.7% |
| 2 Years PostTx (%) | 50.0% | 100.0% | - | 0.0% | - |
| 3 Years PostTx (%) | 0.0% | 100.0% | - | 0.0% | - |
| CyA+Siro | | | | | |
| At Discharge (N) | 1 | 1 | - | 1 | - |
| At Discharge (%) | 100.0% | 100.0% | - | 100.0% | - |
| 6 Months PostTx (%) | 100.0% | - | - | 100.0% | - |
| 1 Year PostTx (%) | - | - | - | 100.0% | - |
| 2 Years PostTx (%) | - | - | - | - | - |
| 3 Years PostTx (%) | - | - | - | - | - |
| Siro+MMF | | | | | |
| At Discharge (N) | 1 | - | 2 | - | - |
| At Discharge (%) | 100.0% | - | 100.0% | - | - |
| 6 Months PostTx (%) | 100.0% | - | 100.0% | - | - |
| 1 Year PostTx (%) | 100.0% | - | 100.0% | - | - |
| 2 Years PostTx (%) | 100.0% | - | 0.0% | - | - |
| 3 Years PostTx (%) | 0.0% | - | 0.0% | - | - |
| Tac+Aza | | | | | |
| At Discharge (N) | - | 2 | - | - | 2 |
| At Discharge (%) | - | 100.0% | - | - | 100.0% |
| 6 Months PostTx (%) | - | 100.0% | - | - | 100.0% |
| 1 Year PostTx (%) | - | 100.0% | - | - | 100.0% |
| 2 Years PostTx (%) | - | 50.0% | - | - | - |
| 3 Years PostTx (%) | - | 50.0% | - | - | - |
| Tac+MMF | | | | | |
| At Discharge (N) | 61 | 62 | 91 | 61 | 79 |
| At Discharge (%) | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| 6 Months PostTx (%) | 86.9% | 78.7% | 89.9% | 86.9% | 88.5% |
| 1 Year PostTx (%) | 75.2% | 70.5% | 84.3% | 73.8% | 78.9% |
| 2 Years PostTx (%) | 55.1% | 62.1% | 72.9% | 62.7% | - |
| 3 Years PostTx (%) | 48.5% | 49.9% | 67.6% | 62.7% | - |
| Tac+Siro | | | | | |
| At Discharge (N) | 18 | 13 | 18 | 16 | 8 |
| At Discharge (%) | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| 6 Months PostTx (%) | 66.7% | 84.6% | 77.8% | 81.3% | 50.0% |

(Continued)

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.

Table 6.6h (Continued)
Persistency of Discharge Regimen by Follow-up Period, 2003 to 2007
Recipients with Pancreas Transplant Alone (PTA) Transplants

| | Year of Transplant | | | | |
|--|--------------------|-------|-------|-------|-------|
| | 2003 | 2004 | 2005 | 2006 | 2007 |
| Discharge Regimen (w/ or w/o Steroid Use) | | | | | |
| Tac+Siro | | | | | |
| 1 Year PostTx (%) | 61.1% | 61.5% | 72.2% | 37.5% | 50.0% |
| 2 Years PostTx (%) | 50.0% | 46.2% | 55.6% | 18.8% | - |
| 3 Years PostTx (%) | 43.8% | 46.2% | 42.9% | - | - |

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.

Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.